ESC 365 - Cardiovascular disease prevention with antihyperglycaemic and cholesterol lowering therapy in type 2 diabetes

ESC Premium Access

Cardiovascular disease prevention with antihyperglycaemic and cholesterol lowering therapy in type 2 diabetes

Event: ESC CONGRESS 2017

Topic: Diabetes, dysglycaemia and metabolic syndrome

Session type: Advances in Science

Date: 28 August 2017

Time: 14:00 - 15:30

Session

5 presentations in this session

State of the Art: cardiovascular disease prevention with antihyperglycaemic and cholesterol lowering therapy in type 2 diabetes

Speaker: Professor D. De Zeeuw (Groningen, NL)

Risk of major cardiovascular events in patients with type 2 diabetes with and without prior cardiovascular events: results from the LEADER trial

Speaker: Professor N. Poulter (London, GB)

SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes

Speaker: Doctor E. Jodar Gimeno (Pozuelo de Alarcon, ES)

Impact of CETP inhibition with evacetrapib in patients with diabetes mellitus: results from ACCELERATE

Speaker: Doctor V. Menon (Cleveland, US)

Cardiovascular outcome trials in type 2 diabetes: lessons learned and questions to ask.

Speaker: Professor L. Ryden (Stockholm, SE)

5 speakers from this session

Professor Dick De Zeeuw

, Groningen (Netherlands (The))

1 presentation

0 follower

Professor Neil Poulter

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

21 presentations

0 follower

Doctor Esteban Jodar Gimeno

Universitary Hospital Quironsalud Madrid, Pozuelo de Alarcon (Spain)

0 follower

Doctor Venu Menon

Cleveland Clinic Foundation, Cleveland (United States of America)

7 presentations

0 follower

Professor Lars Ryden

Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)

31 presentations

0 follower

This platform is supported by